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Introduction
Traditionally, catalysis has been divided in three distinct cat-
egories: heterogeneous, homogeneous, and enzymatic catal-
ysis. Although all three disciplines have been successfully
used for enantioselective transformations, the last two have
found broader applications in the synthesis of high-added-
value enantiopure compounds.[1,2]
In the past thirty five years, metal-catalyzed enantioselec-
tive transformations have enjoyed significant growth as it
was recognized that these are amongst the most efficient
ways to produce enantiomerically pure compounds, culmi-
nating with the 2001 Nobel Prize in Chemistry awarded to
Knowles, Noyori, and Sharpless.[3–5] In recent years, organo-
catalysis has had an increasing success and impact.[6]
Despite all efforts, it remains very difficult to predict the
outcome of a metal-catalyzed enantioselective reaction.
Indeed, the differences in energy involved in the diastereo-
meric transition states leading to both enantiomers of a de-
sired product are too small to be reliably predicted or com-
puted. As a consequence, the number of efficient enantiose-
lective metal catalysts and the corresponding substrates re-
mains disappointingly modest.
To get round the difficulty of predicting the enantioselec-
tivity, combinatorial methodologies have been recently ap-
plied to the discovery and development of new enantioselec-
tive catalysts.[7,8] These studies have highlighted the fact that
many subtle experimental parameters (solvent, counterion,
added salts, etc.) often have a significant and unpredictable
influence on the enantioselectivity of a reaction. These weak
contacts between a catalyst and its “nonbonded” environ-
ment are commonly referred to as the second coordination
sphere.[9]
In contrast to organometallic catalysts, enzymes exquisite-
ly tailor both the first and second coordination spheres of
their active site to afford efficient and selective catalytic sys-
tems. This characteristic is very hard to achieve in homoge-
neous catalysis, in which the steric and electronic control is
mostly limited to the first coordination sphere of the metal.
It is instructive to note that, in bioinorganic chemistry, very
few model systems that faithfully reproduce a metallo-coen-
zymes first coordination sphere are as active and as selec-
tive as the true metalloenzyme in which both the first and
the second coordination sphere have been optimized by evo-
lution.[10]
Biocatalysis offers an attractive alternative to the synthe-
sis of enantiopure products.[2,11,12] In particular, the recent
implementation of directed evolution techniques (combined
with an efficient screening[13] or selection tool[14]) has over-
come some of the inherent limitations of enzymatic catalysis
Abstract: Enzymatic and homogeneous catalysis offer
complementary means to produce enantiopure products.
Incorporation of achiral, biotinylated aminodiphos-
phine–rhodium complexes in (strept)avidin affords
enantioselective hydrogenation catalysts. A combined
chemogenetic procedure allows the optimization of the
activity and the selectivity of such artificial metallo-
enzymes: the reduction of acetamidoacrylate proceeds
to produce N-acetamidoalanine in either 96% ee (R) or
80% ee (S). In addition to providing a chiral second co-
ordination sphere and, thus, selectivity to the catalyst,
the phenomenon of protein-accelerated catalysis (e.g.,
increased activity) was unraveled. Such artificial metal-
loenzymes based on the biotin–avidin technology dis-
play features that are reminiscent of both homogeneous
and of enzymatic catalysis.
Keywords: artificial metalloenzymes · asymmetric catal-
ysis · biotin–avidin technology · chemogenetic optimiza-
tion · hydrogenation
[a] Prof. T. R. Ward
Institute of Chemistry, University of Neuchtel
Av. Bellevaux 51, CP 2, 2007 Neuchtel (Switzerland)
Fax: (+41)32-718-2511
E-mail : thomas.ward@unine.ch
Published in Chemistry - A European Journal 11, issue 13, 3798 - 3804, 2005
which should be used for any reference to this work
1
(e.g., giving access to both enantiomers of the product), thus
significantly expanding the scope of applications.[15–20] A
rough comparison of enzymatic and homogeneous catalysis
is presented in Table 1.
From the considerations outlined in Table 1, it appears
that enzymatic and homogeneous catalysis are, in many re-
spects, complementary. A catalyst which would combine the
best of both these kingdoms may appear as a perfect catalyt-
ic system!
With this goal in mind, artificial metalloenzymes that
combine an organometallic moiety embedded in a protein
environment have received increasing attention recently.[21]
In a biomimetic spirit, both the first and second coordina-
tion spheres may be optimized to produce versatile enantio-
selective catalysts. This novel approach offers several ap-
pealing features:
1) The possibility of dissociating the activity (primarily dic-
tated by the organometallic catalyst precursor) from the
selectivity (governed by the host protein).
2) The use of orthogonal diversity-generating procedures:
molecular biology for the protein optimization as well as
parallel synthesis for the organometallic fragment.
3) A novel approach to exploit weak interactions in enan-
tioselective catalysis.
To unambiguously localize the organometallic moiety
within the host protein, two complementary approaches can
be envisaged (Scheme 1): 1) covalent anchoring and 2)
supramolecular anchoring.
1) Covalent anchoring : Inspired by the early work of
Kaiser,[22] several groups have developed methods to co-
valently modify proteins by incorporating transition-
metal catalysts to yield hybrid catalytic systems with
promising properties. For this purpose, a protein with a
single accessible reactive amino acid residue (typically a
cysteine or a serine residue) is covalently coupled to an
organometallic moiety incorporating a complementary
reactive functionality.[21,23–25]
2) Supramolecular anchoring : To ensure the localization of
the organometallic moiety within the host protein, a
very strong noncovalent guesthost (i.e. , an inhibi-
torprotein) couple should be selected. Since no chemi-
cal coupling step is required upon addition of the cata-
lyst precursor (which contains the inhibitor acting as
anchor) to the protein, the integrity of the organometal-
lic species is warranted.[26] Ideally, the host protein
should possess a deep binding pocket capable of accom-
modating an organometallic moiety. Furthermore, the af-
finity of the inhibitor for the protein should not be too
strongly affected upon coupling of the inhibitor to a
large organometallic moiety.
For supramolecular-anchoring purposes, the biotin–avidin
couple fulfils all of the above requirements. The association
constant of biotin for avidin is the highest known in nature
for a noncovalent interaction (Ka1014m1).[27] In addition
to the six hydrogen-bonding contacts between the protein
and the biotins bicyclic urea framework, the binding pocket
possesses four or five (for streptavidin and avidin, respec-
tively) aromatic residues that make up a deep hydrophobic
box, Figure 1[28,29] The biotin–avidin technology relies pri-
marily on the fact that derivatization of the valeric acid side
chain of biotin does not reduce significantly the affinity of
biotin for (strept)avidin (hereafter (strept)avidin refers to
either avidin or streptavidin).[27] In the biotin–avidin tech-
nology, however, a long spacer (C5 or longer) is usually in-
troduced between the biotin anchor and the conjugated
probe. Additional appealing aspects of the biotin–(strept)-
avidin system include: 1) both proteins have been expressed
in various organisms, 2) the proteins are very robust, and 3)
the proteins are easy to purify by affinity chromatography.
Inspired by Whitesides and Chans early reports, we fo-
cused on artificial metalloenzymes based on biotin–avidin
technology for the hydrogenation of acetamidoacrylic
acid.[30,31]






reaction repertoire small large
turnover number large small
optimization genetic chemical
second coordination sphere well defined ill defined
substrate scope small large
enantiomers single enantiomer both enantiomers
reaction medium mostly aqueous mostly organic
catalyst recovery straightforward difficult
Scheme 1. Anchoring of an active catalyst within a host protein affords
artificial metalloenzymes for enantioselective catalysis. The host protein
displays high affinity for the anchor (triangle); introduction of a spacer
(rectangle) and variation of the ligand scaffold allows to chemically opti-
mize the selectivity of the hybrid catalyst. Site-directed mutagenesis
allows a genetic optimization of the performance of the artificial metal-
loenzyme.
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Artificial Metalloenzymes Based on Biotin–Avidin
Technology
Enantioselective hydrogenation : Two achiral aminodiphos-
phine ligand scaffolds 1 and 2 were selected for screening
purposes (Scheme 2). Upon coordination, the biotinylated
ligand Biot-1 forms an eight-membered ring, thus conferring
significant flexibility to the resulting chelate. In contrast, the
biotinylated ligand Biot-2 is more rigid upon chelation. Six-
membered aliphatic-ring diphosphine ligands are known to
perform poorly in enantioselective catalysis as they often
adopt pseudo-achiral chair conformations.[32, 33]
The first catalytic experiments were performed with com-
mercial egg-white avidin. The results were disappointing as
the enantiomeric excess (ee) did not exceed 39% (S) when
Biot-1 was used (Scheme 2).[30] As the isoelectic point of
avidin is very high (pI=10.4), we suspected that, at neutral
pH, significant amounts of the cationic catalyst precursor
[Rh(Biot-1)(cod)]+ (cod=cyclooctadiene) may not be incor-
porated within the cationic host protein.
We thus turned to streptavidin, a structurally related pro-
tein (30% sequence homology) with a lower isoelectric
point (pI=6.2). To our delight, the hydrogenation of acet-
amidoacrylate in the presence of [Rh(Biot-1)(cod)]+strep-
tavidin (1 mol%) proceeded quantitatively and with good
enantioselectivity (94% ee (R)) (Scheme 2).[34] Combining
both acetamidoacrylic acid with acetamidocinnamic acid
substrates and the use of [Rh(Biot-1)(cod)]+streptavidin
(in 0.1m MES buffer at pH 5.5; MES=2-morpholinoethane-
sulfonic acid) yielded (R)-acetamidoalanine and (R)-acet-
amidophenylalanine in 94% ee (quantitative and 85% con-
version, respectively) in both cases.[35] This suggests that the
artificial metalloenzyme operates indiscriminately on both
substrates, irrespective of their size, reminiscent of homoge-
neous catalysts.
Introduction of an achiral amino acid spacer between the
biotin anchor and the {Rh(diphosphine)} moiety makes it
possible to chemically optimize the selectivity of the artifi-
cial metalloenzyme. For this purpose, five alkylaminoacids
(3n, n=1–5) and three arylaminoacids (4q, q=ortho-, meta-
and para-) were combined with both ligand scaffolds 1 and 2
to afford a total of eighteen biotinylated ligands (including
the ligands Biot-1 and Biot-2, devoid of spacer). Screening
revealed that [Rh(Biot-31–2)(cod)]+avidin affords acet-
amidoalanine in 80% ee (S). This last result demonstrates
that both avidin and streptavidin are suitable host proteins
for the creation of artificial metalloenzymes.
The screening revealed that the pH as well as the nature
of the buffer have some influence on both the yield (
10%) and on the enantioselectivity (5%). Overall, avidin
performs best at neutral pH (0.1m MOPS buffer; MOPS=
3-(N-morpholino)propanesulfonic acid), whereas streptavi-
din performs best at pH 4.0 (0.1m acetate buffer), further
suggesting that the ionization state of the host protein has
little influence on the performance of the artificial metal-
loenzyme.
Chemogenetic optimization procedure : Having validated
the chemical optimization strategy, we next moved to the
genetic optimization of selectivity. For this purpose, four
streptavidin mutants (S112G, V47G, K80G, and P64G) were
expressed in multigram quantities in E. Coli,[36] purified, and
tested in combination with the eighteen above ligands.[37] In
all cases, a loop residue was substituted by a glycine residue,
thus imparting conformational freedom to the correspond-
ing loop.
Figure 1. The biotin–(strept)avidin complex as revealed by X-ray crystal-
lography. One monomer of the tetrameric (strept)avidin structure is de-
picted, emphasizing the eight-stranded b-barrel fold as well as the deep
binding pocket for biotin (ball and stick) in a) avidin (pdb refcode: 1avd)
and b) streptavidin (pdb refcode: 1swd). Close-up view of a biotin bind-
ing pocket in c) avidin and d) streptavidin. Biotin (ball and stick); polar
amino acid residues (green and yellow) interacting with biotins urea
functionality (green residues) and with the valeric acid (yellow residues);
aromatic residues forming the hydrophobic box are highlighted in orange
and red. This last tryptophan residue is supplied by an adjacent monomer
(gold loop), providing a lid to the hydrophobic box.
Scheme 2. Operating conditions and ligands used in conjunction with
(strept)avidin for the hydrogenation of N-acetamidodehydroaminoacids.
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1) Docking experiments suggest that residue S112
(Loop 7,8) lies close to the [Rh(Biot-1)]+ moiety upon
incorporation in streptavidin.
2) Removing a positively charged lysine residue in the vi-
cinity of the active site (K80, Loop 5,6) is expected to in-
fluence to position of the cationic rhodium moiety.
3) The main chain carbonyl group of V47 (Loop 3,4) dis-
plays a second coordination sphere contact with biotin:
it interacts with the critical S45, which, in turn, interacts
with one proton of the urea functionality of biotin.[29]
4) Removing the constraint imposed by a proline (P64,
Loop 4,5) residue may be subtly reflected in the remote
biotin binding site.
In addition to the streptavidin mutants described above, a
recombinant glycosylated form of avidin was expressed in
Pichia pastoris.[38] Four point mutations, K3E, K9D, R122A,
and R124A, as well as an additional E-A-E at its N-termi-
nus yielded an avidin mutant (r-GAvi) with a pI=5.4. In
strong contrast to egg-white avidin, r-GAvi displays a very
narrow glycosylation pattern (primarily Man9-(GlcNAc)2,
Man=mannose, GlcNAc=N-acetylglucosamine).
The results of the screening experiments with acetamido-
acrylate as substrate are summarized using a fingerprint for
each matrix element (187 ligand–protein combinations) in
Figure 2:[39] the strawberry color codes for (S)-acetamidoala-
nine and the green color codes for the (R)-acetamidoala-
nine. The intensity of the color is proportional to the conver-
sion. Such a display format allows the qualitative rapid iden-
tification of the best ligand–protein combinations, as well as
general trends. Inspection of both S112G and V47G vectors
reveals that these two mutants are anticorrelated: the Biot-
1/S112G combination affords (R)-acetamidoalanine in
96% ee, whereas the Biot-1/V47G matrix element affords
(R)-acetamidoalanine in only 26% ee. The couples (Biot-
4ortho–2/S112G (57% ee (S)) and (Biot-4ortho–2/V47G
(44% ee (R)) display the greatest degree of anticorrelation.
The conversions obtained using Biot-4para–2 in combina-
tion with streptavidin and its mutants are moderate (50–
70%) in all but one case (K80G, quant. conversion), sug-
gesting that the catalytic moiety is not very accessible with
this ligand–spacer combination. Despite a lowered isolectric
point and its well-defined glycosylation pattern r-GAvi per-
forms more poorly than WT-Avi.
The above experiments demonstrate that the selectivity of
artificial metalloenzymes is amenable to a chemogenetic op-
timization procedure. Next, we analyzed the effect of the
protein environment on the activity of the hybrid catalyst.
Protein-accelerated catalysis : Both in the areas of homoge-
neous and heterogeneous catalysis, the concept of ligand ac-
celeration has proven valuable.[40,41] In ligand-accelerated
catalysis, the presence of a ligand increases the reaction rate
of a catalytic transformation, which proceeds even in the ab-
sence of added ligand. The same concept may apply for arti-
ficial metalloenzymes as a biotinylated catalyst precursor
(e.g. [Rh(Biot-1)(cod)]+) is active outside its host protein,
producing racemic material (Scheme 3). Assuming that both
competing catalytic cycles (within and without (strept)avi-
din, once all binding sites are saturated) proceed according
to the same mechanism, the ratio of the rates kcatprot/kcat can
be estimated by incrementally varying the [Rh(Biot-1)-
(cod)]+/(strept)avidin ratio. For




acetamidoacrylate in 94% ee
(R) for streptavidin and in
39% ee (S) for avidin) are lo-
cated within the host protein
and four equivalents (producing
racemic material) are located
outside the host protein. As-
suming the same rates
(kcatprot=kcat), the expected ee
for acetamidoacrylate is
(94+0)/2=47% ee for strepta-
vidin and (39+0)/2=20% ee for
avidin. The ees obtained with
eight equivalents biotinylated
catalyst are 75% ee and 36% ee
with streptavidin and with
avidin, respectively. Such an in-
crease of activity of the catalyst
within the protein cavity, re-
flected in the enantiomeric
excess of the product, suggests
Figure 2. Selectivity array (fingerprint) for the reduction of acetamidoacrylate using artificial metalloenzymes
based on the biotin-avidin technology.
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protein-accelerated catalysis.[42] A possible explanation for
this phenomenon may be the presence of a hydrophobic
binding pocket (Figure 1) leading to an accumulation of the
hydrophobic substrate within the host protein. This, in turn,
is reflected by an increase in the rate kcatprot versus kcat. In
the close future, we plan to carry out a thorough kinetic
analysis on such systems. So far, such an analysis has been
hampered by the low solubility of the substrates, preventing
us from varying their concentration over a wide range to ex-
tract the precious kcat and KM parameters.
Outlook
Confronting the observations outlined herein with Table 1
reveals that the artificial metalloenzyme based on biotin–
avidin technology allies features that are reminiscent both
of the enzymatic and homogeneous catalysis.
1) The approach broadens the scope of application of en-
zymes. Incorporation of an active organometallic moiety
(which is compatible with
aqueous media) in a host
protein should ideally allow
us to perform reactions cat-
alyzed by artificial metal-
loenzymes that are unique
to the organometallic king-
dom.
2) The turnover number of the
hybrid catalysts is modest:
1 mol% rhodium is typically
used. This is due to traces of
oxygen that irreversibly
poison the rhodium–diphos-
phine moiety. The hybrid
catalyst can be readily sepa-
rated from the reaction mix-
ture by size-selective filtration. As the biotinylated cata-
lyst is noncovalently bound, a single denaturation–rena-
turation cycle restores biotin-binding activity, thus allow-
ing the protein to be recycled.
3) Chemical and genetic methodologies can be combined
to optimize both the activity and the selectivity of the ar-
tificial metalloenzymes. By using this procedure, both
enantiomers of the product can be obtained.
4) This approach allows us to dissociate the activity from
the selectivity of the hybrid catalyst. The activity is by-
and-large dictated by the biotinylated organometallic
fragment, whereas the selectivity is governed by the host
protein. We speculate that, upon incorporation in the
host protein, the rhodium-bound diphosphine ligand
(which exists as a racemic mixture of d and l conform-
ers) adopts an enantioenriched configuration that favors
the approach of one of the prochiral faces of the sub-
strate, Scheme 4.
Encouraged and stimulated by these findings, we are cur-
rently focusing on mechanistic and structural aspects of the
Scheme 3. The concept of protein-accelerated catalysis. The protein-embedded catalyst [Rh(Biot-1)(cod)]+
(strept)avidin produces enantioenriched reduction product, while the protein-free catalyst [Rh(Biot-1)-
(cod)]+ affords racemic product.
Scheme 4. Upon incorporation in (strept)avidin (gray), the biotinylated chelate (black) adopts an enantioenriched configuration (either l or d) that, in
turn, determines which prochiral face of the substrate (bold) binds to the rhodium.
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hydrogenation reaction. In addition, we are working on C
C bond-forming reactions catalyzed by artificial metallo-
enzymes.
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